LWLu Wang

Lu Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lu Wang has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • University of Washington Nathan Shock Center: innovation to advance aging research

    by Matt Kaeberlein, Alessandro Bitto, Maitreya J. Dunham, Warren Ladiges, Su-In Lee, Michael J. MacCoss, Alexander Mendenhall, Daniel E. L. Promislow, Peter S. Rabinovitch, Judit Villén, et al.

    The University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging provides leadership and resources to support the geroscience community locally, nationally, and internationally. Services are provided through our Resource Cores and funds are available annually to support pilot projects by external investigators. Aging-related studies involving proteomics, metabolomics, invertebrate model organisms, and bioinformatics/artificial intelligence are supported by our Cores. The UW Nathan Shock Center also serves as the administrative home for a Geropathology Research Resource. In addition, the Center works in conjunction with the University of Washington Healthy Aging and Longevity Research Institute to organize and support an annual Seminar Series in the Biology of Aging, an annual 1-day Geroscience Symposium, didactic training for the Biological Mechanisms of Healthy Aging Training Program, and other strategic initiatives. Our Center also supports the American Aging Association Annual Meeting, and we have recently partnered with the American Aging Association and the JAX Aging Center to create a set of video lectures on select topics in geroscience as part of the AGE Presents Video Lecture Series.


  • Open Access

    Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

    by Ying Ann Chiao, Huiliang Zhang, Mariya Sweetwyne, Jeremy Whitson, Ying Sonia Ting, Nathan Basisty, Lindsay Pino, Ellen Quarles, Ngoc-Han Nguyen, Matthew D. Campbell, et al.

    Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.


  • Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice

    by Matthew D. Campbell, Jicheng Duan, Ashton T. Samuelson, Matthew J. Gaffrey, Gennifer E. Merrihew, Jarrett D. Egertson, Lu Wang, Theo K. Bammler, Ronald J. Moore, Collin C. White, et al.


  • Open Access

    Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity

    by Elijah J. Weber, Kevin A. Lidberg, Lu Wang, Theo K. Bammler, James W. MacDonald, Mavis J. Li, Michelle Redhair, William M. Atkins, Cecilia Tran, Kelly M. Hines, et al.

    Drug-induced kidney injury, largely caused by proximal tubular intoxicants, limits development and clinical use of new and approved drugs. Assessing preclinical nephrotoxicity relies on animal models that are frequently insensitive; thus, potentially novel techniques — including human microphysiological systems, or “organs on chips” — are proposed to accelerate drug development and predict safety. Polymyxins are potent antibiotics against multidrug-resistant microorganisms; however, clinical use remains restricted because of high risk of nephrotoxicity and limited understanding of toxicological mechanisms. To mitigate risks, structural analogs of polymyxins (NAB739 and NAB741) are currently in clinical development. Using a microphysiological system to model human kidney proximal tubule, we exposed cells to polymyxin B (PMB) and observed significant increases of injury signals, including kidney injury molecule-1 KIM-1and a panel of injury-associated miRNAs (each P < 0.001). Surprisingly, transcriptional profiling identified cholesterol biosynthesis as the primary cellular pathway induced by PMB ( P = 1.22 ×10 –16 ), and effluent cholesterol concentrations were significantly increased after exposure ( P < 0.01). Additionally, we observed no upregulation of the nuclear factor (erythroid derived-2)–like 2 pathway, despite this being a common pathway upregulated in response to proximal tubule toxicants. In contrast with PMB exposure, minimal changes in gene expression, injury biomarkers, and cholesterol concentrations were observed in response to NAB739 and NAB741. Our findings demonstrate the preclinical safety of NAB739 and NAB741 and reveal cholesterol biosynthesis as a potentially novel pathway for PMB-induced injury. To our knowledge, this is the first demonstration of a human-on-chip platform used for simultaneous safety testing of new chemical entities and defining unique toxicological pathway responses of an FDA-approved molecule.


  • Open Access

    Age- and Genotype-Specific Effects of the Angiotensin-Converting Enzyme Inhibitor Lisinopril on Mitochondrial and Metabolic Parameters in Drosophila melanogaster

    by Karis A. Ederer, Kelly Jin, Sarah Bouslog, Lu Wang, Gregory S. Gorman, Glenn C. Rowe, Peter Abadir, Daniel Raftery, Douglas Moellering, Daniel Promislow, et al.

    The angiotensin-converting enzyme (ACE) is a peptidase that is involved in the synthesis of Angiotensin II, the bioactive component of the renin-angiotensin system. A growing body of literature argues for a beneficial impact of ACE inhibitors (ACEi) on age-associated metabolic disorders, mediated by cellular changes in reactive oxygen species (ROS) that improve mitochondrial function. Yet, our understanding of the relationship between ACEi therapy and metabolic parameters is limited. Here, we used three genetically diverse strains of Drosophila melanogaster to show that Lisinopril treatment reduces thoracic ROS levels and mitochondrial respiration in young flies, and increases mitochondrial content in middle-aged flies. Using untargeted metabolomics analysis, we also showed that Lisinopril perturbs the thoracic metabolic network structure by affecting metabolic pathways involved in glycogen degradation, glycolysis, and mevalonate metabolism. The Lisinopril-induced effects on mitochondrial and metabolic parameters, however, are genotype-specific and likely reflect the drug’s impact on nutrient-dependent fitness traits. Accordingly, we found that Lisinopril negatively affects survival under nutrient starvation, an effect that can be blunted by genotype and age in a manner that partially mirrors the drug-induced changes in mitochondrial respiration. In conclusion, our results provide novel and important insights into the role of ACEi in cellular metabolism.